Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Hansoh Xinfu (flumatinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Jiangsu Hansoh Pharma, Jiangsu Hengrui Pharma

Drug class:

c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor

Related drugs:

‹

›

BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	flumatinib Sensitive: C3 – Early Trials flumatinib Sensitive : C3	flumatinib Sensitive: C3 – Early Trials flumatinib Sensitive : C3
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	flumatinib Sensitive: C3 – Early Trials flumatinib Sensitive : C3	flumatinib Sensitive: C3 – Early Trials flumatinib Sensitive : C3
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	venetoclax + flumatinib Sensitive: C3 – Early Trials venetoclax + flumatinib Sensitive : C3	venetoclax + flumatinib Sensitive: C3 – Early Trials venetoclax + flumatinib Sensitive : C3
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	venetoclax + flumatinib Sensitive: C3 – Early Trials venetoclax + flumatinib Sensitive : C3	venetoclax + flumatinib Sensitive: C3 – Early Trials venetoclax + flumatinib Sensitive : C3
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	flumatinib Sensitive: C3 – Early Trials flumatinib Sensitive : C3	flumatinib Sensitive: C3 – Early Trials flumatinib Sensitive : C3